Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/36600
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYoon S.en
dc.contributor.authorKwan A.en
dc.contributor.authorLi C.C.en
dc.contributor.authorSison I.en
dc.contributor.authorWei M.C.en
dc.contributor.authorYin S.en
dc.contributor.authorYousefi K.en
dc.contributor.authorKim W.S.en
dc.contributor.authorAssouline S.en
dc.contributor.authorBartlett N.L.en
dc.contributor.authorBosch F.en
dc.contributor.authorBudde L.E.en
dc.contributor.authorCheah C.en
dc.contributor.authorGregory G.P.en
dc.contributor.authorHong J.en
dc.contributor.authorKu M.en
dc.contributor.authorMarlton P.en
dc.contributor.authorMatasar M.en
dc.contributor.authorNastoupil L.en
dc.contributor.authorPanizo C.en
dc.contributor.authorSehn L.H.en
dc.contributor.authorTzachanis D.en
dc.contributor.authorChu W.en
dc.contributor.authorHernandez M.G.en
dc.date.accessioned2021-05-14T12:25:09Zen
dc.date.available2021-05-14T12:25:09Zen
dc.date.copyright2019en
dc.date.created20190813en
dc.date.issued2019-08-13en
dc.identifier.citationHematological Oncology. Conference: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi. Lugano Switzerland. 37 (Supplement 2) (pp 567-568), 2019. Date of Publication: June 2019.en
dc.identifier.issn1099-1069en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/36600en
dc.description.abstractBackground: Mosunetuzumab is a novel CD20/CD3 bispecific antibody that directs T-cells to engage and eliminate malignant B-cells. Interim results from an ongoing, open-label, multicentre, phase 1/1b study (NCT02500407; GO29781) indicate that mosunetuzumab monotherapy administered intravenously (IV) induces durable complete responses with favourable safety in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) (Budde et al. ASH 2018). We report details of 2 other ongoing dose-escalation groups from this study: Group D assesses mosunetuzumab administered subcutaneously (SC) as an approach intended to minimize cytokine-driven toxicities; Group E combines mosunetuzumab and atezolizumab for potentially enhanced clinical efficacy with the addition of immune checkpoint blockade. Dose-expansion cohorts in patients with R/R diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (tFL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) are ongoing. Method(s): Patients with R/R NHL (age >=18 years; ECOG performance status of 0 or 1) in Group D receive a fixed dose of mosunetuzumab SC on Day 1 of each 21-day cycle, up to a maximum of 17 cycles; patients in Group E receive ascending doses of mosunetuzumab IV on Day 1, Day 8 and Day 15 of Cycle 1 (step-up dosing), then from Cycle 2 onwards, a fixed dose on Day 1 of every 21-day cycle with concurrent administration of atezolizumab (1200 mg IV), up to a maximum of 17 cycles. Primary outcome measures are maximum tolerated dose (MTD) based on dose-limiting toxicities, tolerability, pharmacokinetics and best objective response. Dose-expansion cohorts are enrolling patients with R/R DLBCL/tFL, FL, or MCL and patients will receive doses of mosunetuzumab up to the MTD. Details of patient enrolment for the dose-escalation and dose-expansion cohorts are provided (Table).en
dc.languageEnglishen
dc.languageenen
dc.publisherJohn Wiley and Sons Ltden
dc.titleAn ongoing phase 1/1b trial investigating novel treatment regimens with mosunetuzumab in relapsed/refractory B-cell nonhodgkin lymphoma.en
dc.typeConference Abstracten
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1002/hon.15_2632en
local.date.conferencestart2019-06-18en
dc.identifier.source628866890en
dc.identifier.institution(Kim) Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea (Assouline) Division of Hematology, Jewish General Hospital, Montreal, QC, Canada (Bartlett) Siteman Cancer Center, Washington University, School of Medicine in St. Louis, St. Louis, MO, United States (Bosch) Department of Hematology, University Hospital Vall D'Hebron, Barcelona, Spain (Budde) Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States (Cheah) Linear Clinical Research and School of Medicine, University of Western Australia, WA, Australia (Gregory) School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (Hong) Department of Oncology, ASAN Medical Center, Seoul, South Korea (Ku) Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia (Marlton) Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia (Matasar) Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States (Nastoupil) Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX, United States (Panizo) Haemotology and Haemotherapy Department, Clinica Universidad De Navarra, Pamplona, Spain (Sehn) Medical Oncology, BC Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver, BC, Canada (Tzachanis) Department of Medicine, University of California San Diego, San Diego, CA, United States (Chu, Hernandez, Kwan, Li, Sison, Wei, Yin) Product Development Oncology,Genentech,Inc., South San Francisco, CA, United States (Yousefi) Product Development,Biometrics,Biostatistics,Genentech,Inc., South San Francisco, CA, United States (Yoon) Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Koreaen
dc.description.addressW.S. Kim, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Koreaen
dc.description.publicationstatusCONFERENCE ABSTRACTen
local.date.conferenceend2019-06-22en
dc.rights.statementCopyright 2019 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCD20 Non-Hodgkin lymphoma (NHL)en
dc.identifier.affiliationext(Kim) Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea-
dc.identifier.affiliationext(Assouline) Division of Hematology, Jewish General Hospital, Montreal, QC, Canada-
dc.identifier.affiliationext(Bartlett) Siteman Cancer Center, Washington University, School of Medicine in St. Louis, St. Louis, MO, United States-
dc.identifier.affiliationext(Bosch) Department of Hematology, University Hospital Vall D'Hebron, Barcelona, Spain-
dc.identifier.affiliationext(Budde) Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, United States-
dc.identifier.affiliationext(Cheah) Linear Clinical Research and School of Medicine, University of Western Australia, WA, Australia-
dc.identifier.affiliationext(Hong) Department of Oncology, ASAN Medical Center, Seoul, South Korea-
dc.identifier.affiliationext(Ku) Department of Haematology, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia-
dc.identifier.affiliationext(Marlton) Department of Medicine, University of Queensland, Princess Alexandra Hospital, Brisbane, QLD, Australia-
dc.identifier.affiliationext(Matasar) Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States-
dc.identifier.affiliationext(Nastoupil) Department of Lymphoma and Myeloma, University of Texas, MD Anderson Cancer Center, Houston, TX, United States-
dc.identifier.affiliationext(Panizo) Haemotology and Haemotherapy Department, Clinica Universidad De Navarra, Pamplona, Spain-
dc.identifier.affiliationext(Sehn) Medical Oncology, BC Cancer Centre for Lymphoid Cancer, University of British Columbia, Vancouver, BC, Canada-
dc.identifier.affiliationext(Tzachanis) Department of Medicine, University of California San Diego, San Diego, CA, United States-
dc.identifier.affiliationext(Chu, Hernandez, Kwan, Li, Sison, Wei, Yin) Product Development Oncology,Genentech,Inc., South San Francisco, CA, United States-
dc.identifier.affiliationext(Yousefi) Product Development,Biometrics,Biostatistics,Genentech,Inc., South San Francisco, CA, United States-
dc.identifier.affiliationext(Yoon) Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea-
dc.identifier.affiliationmh(Gregory) School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeConference Abstract-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Conferences
Show simple item record

Page view(s)

102
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.